Fulgent Genetics (DE:7F0)
NASDAQ:7F0
Earnings Data
Report Date
Jul 31, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.39Last Year’s EPS
0.06Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: operational headwinds in Q1 (revenue declines, margin pressure, an ongoing transition of a large customer and short-term cash outflows for acquisition and buybacks) were balanced by strategic positives (completed acquisitions that expand pathology capacity and salesforce, strong cash balance, reiterated full-year revenue guidance, notable progress in the therapeutic pipeline with ASCO recognition, AI/product innovations and regulatory/pricing wins for PGx tests). Management expects normalization of margins and revenue growth in H2 driven by acquisition contribution and backlog clearance, but near-term volatility and losses remain evident.Company Guidance
Strategic Acquisitions Completed
Completed acquisition of Bako Diagnostics and StrataDx in Q1 2026, adding $2.6M of revenue in the quarter, more than doubling the pathology sales team, expanding Anatomic Pathology market presence, and expected to contribute ~ $53M to revenue in H2 2026.
Strong Cash Position Despite Uses
Ended Q1 with $604.7M in cash, cash equivalents, restricted cash and marketable securities; management forecasts ending 2026 cash of ~$636M (assuming receipt of delayed tax refund and no further extraordinary expenditure).
Therapeutic Pipeline Momentum (FID-007 & FID-022)
FID-007 completed Phase II enrollment (46 patients) with encouraging early efficacy/safety; selected for rapid oral presentation at ASCO; plan for end-of-Phase-II FDA meeting in H2 2026 and potential Phase III start in H1 2027. FID-022 has completed dose level 3 and is in dose escalation with MTD expected later in 2026.
Reiterated 2026 Revenue Guidance
Reiterated full-year 2026 revenue guidance of $350M (implying ~8.5% year-over-year growth) and provided segment revenue targets: Precision Diagnostics ~$168M, Anatomic Pathology ~$162M, Biopharma Services ~$20M.
AI and Product Innovation Progress
In-house EasioPath platform is ~100% visual across cases; launched dermatopathology AI auto-rotation tool in Q1; integrated Illumina TruPath Genome into new whole genome test to deliver comprehensive single-report genomic insights across 20,000 genes.
Regulatory/Market Win for Pharmacogenomics
Received MolDX approval and pricing for PGx test (DPYD) in Q1 and benefits from shifting clinical guidance (ASCO/NCCN/FDA trends) that increase addressable market for DPYD pharmacogenomic testing.
Share Repurchase and Lower Share Count
Repurchased 2.6M shares in Q1 and an additional 0.5M to date; updated forecasted average diluted share count for 2026 reduced from ~32M to ~29M, resulting in a $0.14 per-share impact to non-GAAP EPS guidance.
DE:7F0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:7F0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2026 | €12.60 | €12.60 | 0.00% |
Feb 27, 2026 | €19.70 | €14.90 | -24.37% |
Nov 07, 2025 | €19.60 | €20.60 | +5.10% |
Aug 01, 2025 | €15.30 | €17.30 | +13.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fulgent Genetics (DE:7F0) report earnings?
Fulgent Genetics (DE:7F0) is schdueled to report earning on Jul 31, 2026, After Close (Confirmed).
What is Fulgent Genetics (DE:7F0) earnings time?
Fulgent Genetics (DE:7F0) earnings time is at Jul 31, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Fulgent Genetics stock?
The P/E ratio of Fulgent Genetics is N/A.
What is DE:7F0 EPS forecast?
DE:7F0 EPS forecast for the fiscal quarter 2026 (Q2) is -0.39.